

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.27%
+0.61%
+3.26%
-10.82%
-8.09%
WST
West Pharmaceutical
$302.04
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Chart
$262.33 (+15.14%)
$244.05 (+23.76%)
$211.45 (+42.84%)
$323.93 (-6.76%)
WST has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

WST overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Eps growth
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
WST Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
WST Street view is extremely bullish and have positive views on the near-term outlook
WST Earnings
The TTM reflects 12-month period, providing review of WST financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is WST current stock price?
What are WST stock strengths?
What risks are associated with WST stock?
When is WST next earnings report?
What is WST market cap and volume?
What is WST's current Stock IQ?
Should I buy WST stock right now?
Is WST a Strong Buy right now?
What does a 'Strong Buy' rating mean for WST?
What does a 'Strong Sell' rating mean for WST?
What factors influence WST's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.27%
+0.61%
+3.26%
-10.82%
-8.09%
WST
West Pharmaceutical
Current Price
$302.04
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
Chart
$262.33 (+15.14%)
$244.05 (+23.76%)
$211.45 (+42.84%)
$323.93 (-6.76%)
WST Analysts Opinion
WST Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Eps growth
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
WST Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
WST Street view is extremely bullish and have positive views on the near-term outlook
WST has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

WST Earnings
The TTM data reflects the most recent 12-month period, providing overview of WST financial performance.
WST Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
WST Latest Analysis
West Pharmaceutical Services Inc. (NYSE:WST) Q3 2025 Earnings Call Transcript. West Pharmaceutical Services Inc. (NYSE:WST) Q3 2025 Earnings Call Transcript October 23 2025 West Pharmaceutical Services Inc. beats earnings expectations. Reported EPS is $1.96 expectations were $1.67. Operator: Good day and welcome to West’.s Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder this call may be recorded. I would now like to [….]
Today
Evercore ISI Group Maintains West Pharmaceutical Services (WST) Outperform Recommendation. Fintel reports that on October 23 2025 Evercore ISI Group maintained coverage of West Pharmaceutical Services (NYSE:WST) with a Outperform recommendation. Analyst Price Forecast Suggests 4.22% Upside
Today
West to Participate in Upcoming Investor Conferences. EXTON Pa. Oct. 24 2025 /PRNewswire/ -- West Pharmaceutical Services Inc. (NYSE: WST) a global leader in innovative solutions for injectable drug administration today announced that it will present at the following upcoming investor conferences: UBS Global Healthcare Conference:...
Today
Why West Pharmaceutical Services Stock Was Blasting Higher on Thursday. Key PointsIt was a beat-and-raise third quarter for the healthcare services specialist.
Thu Oct 23, 2025
West Pharmaceutical raises 2025 EPS guidance to $7.06-$7.11 amid strong HVP Components growth.
Thu Oct 23, 2025
West Pharma Soars After Q3 Beat Lifts Outlook On GLP-1 Demand. WST) shares surged Thursday after the injectable pharmaceutical packaging and delivery systems company’.s third-quarter 2025 earnings surpassed analyst estimates.West Pharmaceutical reported adjusted earnings of $1.96 per share beating the consensus of $1.68.Net sales of $804.6 million increased 7.7% year over year with organic growth was 5.0% beating the consensus of $787.93 million.“.Our strength was broad-based across bo
Thu Oct 23, 2025
S&P 500 Movers: MOH WST. In early trading on Thursday shares of West Pharmaceutical Services topped the list of the days best performing components of the S&.P 500 index trading up 15.5%. Year to date West Pharmaceutical Services has lost about 2.3% of its value.And the worst performing S&
Thu Oct 23, 2025
WST Stock Up on Q3 Earnings Beat EPS View Raised on Demand & FX Benefit. West Pharmaceuticals strong Q3 beat and raised EPS outlook highlight robust demand FX tailwinds and solid growth in Proprietary Products.
Thu Oct 23, 2025
West Pharmaceutical Non-GAAP EPS of $1.96 beats by $0.27 revenue of $804.6M beats by $16.9M.
Thu Oct 23, 2025
West Reports Third-Quarter 2025 Results. - Delivered solid growth across Proprietary Products and Contract Manufacturing Segments - - Achieved double-digit growth in HVP Components -- Strengthened executive leadership team including recently appointed CFO - Increases Full-Year 2025 Revenue and EPS Guidance - Third-Quarter Summary (comparisons to prior-year period)Net sales of Diluted EPS of Adjusted-diluted EPS of Full-year 2025 net sales guidance increased to a range of Full-year 2025 adjust
Thu Oct 23, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.